Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy

ConclusionThis case illustrates that a fulminant response to combined checkpoint inhibition is possible after progression after anti-PD-1 monotherapy and a severe irAE.

Source: Journal for Immunotherapy of Cancer - July 11, 2019 Category: Cancer & Oncology Source Type: research